ZLY025 is a potent and orally active CCNK molecular glue degrader with an DC50 of 42.7 nM. ZLY025 exhibits broad-spectrum antiproliferative activity against various tumor cells with IC50 values ranging from 0.08 to 2.45 μM. ZLY025 can induce cells apoptosis and G1 phase arrest. ZLY025 can be used for the research of cancer, such as lung cancer.

ZLWH-67 is a β-Carboline derivative and Antibacterial agent. ZLWH-67 inhibits DNA synthesis, suppresses biofilm formation, and increases reactive oxygen species (ROS) levels. ZLWH-67 exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL), and S. pneumoniae (MIC = 16 μg/mL). ZLWH-67 displays anti-MRSA effects in murine skin and pneumonia infection models.

ZK-Thiazolidinone is an ATP-competitive Polo-like kinase 1 (Plk1) inhibitor with an IC50 of 19 nM. ZK-Thiazolidinone inhibits tumor cell proliferation, induces cell cycle arrest and typical mitotic defects. ZK-Thiazolidinone impairs the recruitment of γ-tubulin and Aurora A kinase to centrosomes, resulting in failure of bipolar spindle maintenance and sister chromatid arm cohesion.\nZK-Thiazolidinone is applicable for cancer research.

ZAK-IN-2 (Compound 8) is a selective, covalent ZAK inhibitor with an IC50 of 11.5 nM. ZAK-IN-2 forms a covalent bond with Cys22 in the P-loop of ZAK to inhibit its kinase activity. ZAK-IN-2 inhibits the phosphorylation of the downstream target p38. ZAK-IN-2 blocks Doxorubicin-induced cleavage of Caspase 3. ZAK-IN-2 is applicable to research related to myocardial hypertrophy.

Z226407860 is a RING-box protein 1 (RBX1) inhibitor. Z226407860 reduces house dust mite-induced airway epithelial injury and ROS accumulation by inhibiting RBX1. Z226407860 can be used for the research of asthma.

YZ-836P is a Protein arginine methyltransferase 5 (PRMT5) targeting agent. YZ-836P promotes ubiquitination and proteasomal degradation of PRMT5 in a cereblon (CRBN)-dependent manner, which in turn reduces levels of its downstream target KLF5. YZ-836P induces G1 phase cell cycle arrest in triple-negative breast cancer cells. YZ-836P induces apoptosis in triple-negative breast cancer cells. YZ-836P exerts cytotoxic effects on triple-negative breast cancer cells. YZ-836P inhibits the growth of triple-negative breast cancer patient-derived organoids. YZ-836P inhibits the growth of triple-negative breast cancer xenografts in nude mice. YZ-836P can be used for the research of triple-negative breast cancer.

YM-1758735 is an orally active androgen receptor (AR) antagonist with an IC50 of 0.2 μM. YM-1758735 inhibits AR-mediated transcriptional activation. YM-1758735 can be used for the research of prostate.

YCH3292, a derivative of YCH189 is a potent, selective and orally active PARP1/2 inhibitor with IC50 both <0.001 nM. YCH3292 can increase the stability of PARP-DNA complexes. YCH3292 exhibits robust antiproliferative activity. YCH3292 can induce double-strand breaks in DNA, increase the protein levels of γH2AX, P-RPA32, and P-Chk1 and induce tumor cells S or G2/M phase arrest and apoptosis. YCH3292 can inhibit tumor growth in MC38 xenograft model.

YAP/TEAD-IN-2 (Compound T-1) is a YAP/TEAD inhibitor. YAP/TEAD-IN-2 inhibits the luciferase activity driven by YAP/TEAD in 293T cells. YAP/TEAD-IN-2 exhibits strong anti-proliferative activity against human pleural mesothelioma NCI-H226 cells. YAP/TEAD-IN-2 can be used for the study of diseases associated with Hippo pathway dysregulation, particularly cancers.

YAP/TAZ-TEAD-IN-3 is a YAP/TAZ-TEAD interaction inhibitor with an IC50 of 1.8 nM. YAP/TAZ-TEAD-IN-3 can be used as a TEAD1 ligand to construct PROTACs, such as PROTAC TEAD degrader-2.

Y502-3888 is a c-Myc inhibitor. Y502-3888 binds to the c-Myc G4 structure, inhibits c-Myc transcription, and downregulates c-Myc expression at both mRNA and protein levels. Y502-3888 inhibits the viability of myeloma cells and induces cell apoptosis. Y502-3888 can be used for the research of multiple myeloma.

XL541 is a potent, selective S1P1 antagonist. XL541 inhibits GDP-GTP exchange. XL541 causes frank surface hemorrhaging of tumors. XL541 collaborates with Paclitaxel to exhibit antitumor activity against breast cancer and lung cancer.

WRN-IN-23 is a Werner Syndrome helicase enzyme (WRN) inhibitor. WRN-IN-23 inhibits the ATP-dependent helicase domain activity of WRN. WRN-IN-23 can be used for the research of cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR).

WMK-2 is a 1,2,4,5-tetraoxane derivative and ferroptosis inducer with broad-spectrum anticancer activity. WMK-2 generates hydroxyl radicals and lipid ROS to induce ferroptosis in cancer cells and cancer stem cells. WMK-2 can be used for the research of cancer.

WEE1/PKMYT1-IN-2 is the axial chiral P configuration of WEE1/PKMYT1-IN-1. WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity.

WB2838 is a non-steroidal androgen-receptor antagonist (IC50: 0.8 μM for partially purified rat prostate cytosol receptor). WB2838 exhibits anti-cancer activity against androgen-responsive breast cancer. WB2838 also shows the inhibitory activity against the growth of the ventral prostate induced by Testosterone propionate.

Vrucaparib-TP4 (Compound 9) is a PARP1 PROTAC-type degrader. Vrucaparib-TP4 promotes the ubiquitination and degradation of PARP1. Vrucaparib-TP4 can be used in the research of tumors. (Pink: PARP and PARP-1 and PARP-2 and PARP-3 ligand ; Blue: VHL ligand ; Black: linker ).

VHL Ligand 35 (Compound 14) is a von Hippel-Lindau protein (pVHL) E3 ubiquitin ligase ligand with a Kd of 0.291 μM. VHL Ligand 35 disrupts protein-protein interaction between pVHL and hypoxia inducible factor 1α (HIF-1α).

UNPD139734 is a CDK-1 inhibitor and PARP-1 inhibitor that forms stable complexes with each target protein. UNPD139734 serves as a lead compound for structural optimization to develop dual-target anticancer agents targeting CDK-1 and PARP-1.UNPD139734 can be used for the research of breast cancer.

UK 343664 is a potent, orally active and selective PDE5 inhibitor. UK 343664 partially reverses Thromboxane-induced pulmonary hypertension.

U-19052 is a selective competitive peptidoleukotriene D/E receptor antagonist. U-19052 acts as a reversible antagonist that not affecting responses to non-leukotriene agonists. U-19052 does not exhibit agonist activity or induce contraction in guinea pig tracheal or ileal strips. U-19052 is a leukotriene antagonist developed by modifying leukotriene chemical structure. U-19052 can be used for the research of allergic asthma and hypersensitivity diseases.

Tubulin polymerization-IN-86 (Compound B6) is an effective inhibitor of tubulin polymerization. Tubulin polymerization-IN-86 effectively inhibits microtubulin polymerization by binding to the colchicine binding sites on microtubulin, thereby disrupting the microtubule cytoskeleton within the cell. Tubulin polymerization-IN-86 exhibits potent anti-proliferative activity against a variety of cancer cell lines. Tubulin polymerization-IN-86 induces cell cycle arrest, apoptosis, inhibits cell migration, invasion, and long-term survival ability. Tubulin polymerization-IN-86 inhibits tumor growth in mice and can be used for the study of melanoma.

Tubulin polymerization-IN-84 inhibits tubulin polymerization by targeting the colchicine-binding pocket, with anIC50 = 10.9 μM. Tubulin polymerization-IN-84 shows antiproliferative activity against Jurkat, B16-F10, HCT116, and MDA-MB-231 cells (IC50 = 60 nM, 380 nM, 138 nM, and 1.054 μM). Tubulin polymerization-IN-84 induces G2/M-phase arrest and apoptosis in B16-F10 cells. Tubulin polymerization-IN-84 suppresses tumor growth in a B16-F10 melanoma model and potentiates anti-tumor immunity in combination with a PD-L1 mAb for the research of T-cell acute lymphoblastic leukemia, melanoma, colon cancer, and breast cancer.

Tuberactinomycin-O is a peptide antibiotic belonging to the tuberactinomycin family. Tuberactinomycin-O inhibits the growth of various bacteria, including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Mycobacterium ATCC 607. Tuberactinomycin-O exhibits acute toxicity in male mice when administered intravenously. Tuberactinomycin-O can be used in the research of tuberculosis.

TSL2109 is an orally active and selective DYRK2 and CDK4/6 inhibitor with an IC50 value of 22 nM for DYRK2. TSL2109 exhibits high kinase selectivity over 93%. TSL2109 arrests cell cycle and induces apoptosis in virto. TSL2109 effectively overcomes Enzalutamide resistance by suppressing tumor growth in vivo and virto. TSL2109 also shows CDK4/6 inhibitor resistance.TSL2109 demonstrates safety profile. TSL2109 can be used for prostate cancer research and breast cancer[1][2].

TRβ agonist-4 is an orally bioavailable, liver-targeted selective agonist of hTHR-β (EC50=6.0 nM), with a 105.3-fold selectivity over THR-α. TRβ agonist-4 exists in multiple crystal forms, including Form A, Form B, Form C, Form D, Form E, as well as an amorphous form. TRβ agonist-4 can be used for research related to non-alcoholic steatohepatitis (NASH).

TRPM8 receptor agonist-1 (Example 81) is a TRPM8 receptor agonist. TRPM8 receptor agonist-1 can trigger the inward flow of calcium, sodium and other ions within the cell, causing the cell membrane to depolarize and triggering an action potential. TRPM8 receptor agonist-1 can activate signals related to the swallowing reflex and can be used for the research of oropharyngeal dysphagia.

TRG-192 is a potent and selective glutaminase (GLS) inhibitor with an IC50 of 68 nM. TRG-192 inhibits intracellular glutamate levels. TRG-192 is applicable to related research on non-small cell lung cancer.

trans-4-[[(1,1-Dimethylethoxy)carbonyl]amino]cyclohexaneacetic acid is a PROTAC linker that can be used in the synthesis of PROTACs.

trans-2-Methoxycinnamic acid (Compound 6) is a trans-cinnamic acid derivative. trans-2-Methoxycinnamic acid inhibits α-glucosidase with an IC50 of 4.34 mM. trans-2-Methoxycinnamic acid can be used in the research of HIV infection and hyperglycemia.